Efficacy of &lt;i&gt;Saccharomyces boulardii&lt;/i&gt; CNCM I-745 probiotic drug in the prevention and treatment of diarrhea in hospitalized patients with new coronavirus infection COVID-19

Маев, И. В.; Andreev, D. N.; Sokolov, Philipp S.; Fomenko, Aleksei К.; Devkota, Mikhail K.; Andreev, Nikolai G.; Заборовский, Андрей Владимирович

doi:10.26442/00403660.2022.10.201881

Cited by 2 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through our meta-analysis, the results showed that probiotics could improve the overall symptoms of COVID-19 patients and shorten the duration of symptoms. For gastrointestinal symptoms, the pooled results of five studies ( 22 – 24 , 29 , 30 ) confirmed that probiotics could obviously reduce the duration of diarrhea in COVID-19 patients. Good consistency exists among the studies, indicating that the results are stable.…”

Section: Discussionmentioning

confidence: 76%

“…Five studies ( 22 , 25 , 28 , 30 , 31 ) reported the hospital stay (days). A total of 776 patients included, 387 in the probiotics group and 389 in the non-probiotics group.…”

Section: Resultsmentioning

confidence: 99%

“…We further analyzed the duration (days) of specific symptoms during the probiotic intervention ( Table 3 ). Five studies ( 22 – 24 , 29 , 30 ) including 200 patients reported the duration of diarrhea. When we examined the two groups using Cochrane's Q test, no obvious heterogeneity was detected among the five studies.…”

Section: Resultsmentioning

confidence: 99%

“…In addition, 4 articles with unavailable data were excluded. Finally, ten qualified published studies (22)(23)(24)(25)(26)(27)(28)(29)(30)(31) were included in the metaanalysis. Figure 1 illustrates the study selection process.…”

Section: Literature Search and Screeningmentioning

confidence: 99%

“…Ten studies (22)(23)(24)(25)(26)(27)(28)(29)(30)(31) comprising 1,453 patients with COVID-19 were included in the analysis. They were carried out in 7 different countries, namely, Russia, Mexico, China, Spain, United States, Rome and Iran.…”

Section: Literature Characteristics and Quality Assessmentmentioning

confidence: 99%

See 4 more Smart Citations

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundMulti system symptoms such as gastrointestinal tract and respiratory tract exist in coronavirus disease 2019 (COVID-19) patients. There is a lack of reliable evidence to prove that probiotics are effective in improving these symptoms. In this study, we aimed to evaluate the efficacy of probiotics in meta-analysis.MethodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to February 15, 2023. Randomized controlled trials or high quality retrospective studies comparing the efficacy of probiotics as supplementation with non-probiotics in improving symptoms for patients with COVID-19 were included. This meta-analysis assessed endpoints using Review Manager 5.3.ResultTen citations comprising 1198 patients with COVID-19 were included. The results showed that probiotics could increase the number of people with overall symptom improvement (RR = 1.62, 95% CI [1.10, 2.38], P = 0.01) and shorten the duration (days) of overall symptoms (MD = −1.26, 95% CI [−2.36, −0.16], P = 0.02). For the duration (days) of specific symptoms, probiotics could improve diarrhea (MD = −2.12, 95% CI [−2.41, −1.83], P < 0.00001), cough (MD = −2.21, 95% CI [-4.56, 0.13], P = 0.06) and shortness of breath (MD = −1.37, 95% CI [-2.22, −0.53], P = 0.001). Probiotics had no obvious effect on fever, headache and weakness. For inflammation, probiotics could effectively reduce C-reactive Protein (CRP) serum level (mg/L) (MD = −4.03, 95% CI [−5.12, −2.93], P < 0.00001). Regarding hospital stay (days), probiotics group was shorter than non-probiotics group (MD = −0.98, 95% CI [−1.95, −0.01], P = 0.05).ConclusionTo some extent probiotics could improve the overall symptoms, inflammatory reaction and shorten hospital stay of patients with COVID-19. Probiotics may improve gastrointestinal symptoms (such as improving intestinal flora and reducing the duration of diarrhea) and further improve respiratory symptoms through the gut-lung axis.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=398309, identifier: CRD42023398309.

show abstract

Section: Discussionmentioning

confidence: 76%

“…Five studies ( 22 , 25 , 28 , 30 , 31 ) reported the hospital stay (days). A total of 776 patients included, 387 in the probiotics group and 389 in the non-probiotics group.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Literature Search and Screeningmentioning

confidence: 99%

Section: Literature Characteristics and Quality Assessmentmentioning

confidence: 99%

See 3 more Smart Citations

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era

Kanauchi,

Low,

Jounai

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

The COVID-19 outbreak has caused significant global changes and increased public awareness of SARS-CoV-2. Substantial progress in developing vaccines, enhancing sanitation practices, and implementing various measures to combat the virus, including the utilization of probiotics has been made. This comprehensive review examined the medical impact of clinically proven probiotics on infectious diseases, considering three crucial time periods: before (pre-), during (mid-), and after (post-) COVID-19 pandemic era. This review also showed a perspective on the use of probiotics to stimulate the innate immune system and prevent infectious diseases. In pre-COVID-19 era, several probiotic strains were found to be clinically effective in addressing gastrointestinal infectious diseases, the common cold and flu. However, the mechanism by which probiotics exerted their antiviral effects remained relatively unclear during that period. Nevertheless, probiotics, Lactococcus lactis strain Plasma (LC-Plasma), and others have gained attention for their unique ability to modulate the immune system and demonstrate antiviral properties. While some probiotics have shown promise in alleviating gastrointestinal symptoms linked to COVID-19, their direct effectiveness in treating or preventing COVID-19 progression has not yet been conclusively established. As we transition into the post-COVID-19 era, the relationship between COVID-19 and plasmacytoid dendritic cells (pDCs), a vital component of the innate immune system, has been gradually elucidated. These findings are now being applied in developing novel vaccines and treatments involving interferons and in immune activation research using probiotics as adjuvants, comparable to CpG-DNA through TLR9. The role of the local innate immune system, including pDCs, as the first line of defense against viral infections has gained increasing interest. Moving forward, insight of the immune system and the crosstalk between probiotics and the innate immune system is expected to highlight the role of probiotics in adjunctive immunoregulatory therapy. In combination with drug treatments, probiotics may play a more substantial role in enhancing immune responses. The immunoregulatory approach using probiotics such as LC-Plasma, which can induce anti-infectious factors such as interferons, holds promise as a viable therapeutic and prophylactic option against viral infectious diseases due to their good safety profile and protective efficacy.

show abstract

Efficacy of <i>Saccharomyces boulardii</i> CNCM I-745 probiotic drug in the prevention and treatment of diarrhea in hospitalized patients with new coronavirus infection COVID-19

Cited by 2 publications

References 31 publications

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Overview of anti-viral effects of probiotics via immune cells in pre-, mid- and post-SARS-CoV2 era

Contact Info

Product

Resources

About